NCCN Offers Free Patient Assistance Resource App
NCCN has launched its Reimbursement Resource App, which offers patients, providers, case managers, and payers access to payment assistance and reimbursement programs for multiple cancer types; the app is available free of charge for Apple and Android mobile devices.
Article ID: 619425
Released: 18-Jun-2014 12:05 PM EDT
Source Newsroom: National Comprehensive Cancer Network® (NCCN®)
Newswise — FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) announces the availability of the NCCN Reimbursement Resource App, a free resource through which patients with cancer, providers, case managers, and payers can search for available reimbursement resources and patient assistance programs for multiple cancer types and supportive care indications. The app is available free of charge via the Apple Store™ and Google Play™ Store and can be found by searching “NCCN Reimbursement.”
“Patients with cancer and their caregivers continue to struggle with the financial burden of a cancer diagnosis,” said C. Lyn Fitzgerald, MJ, Vice President, U.S. and Global Development, NCCN. “By making the NCCN Reimbursement Resource App available free of charge, NCCN seeks to assist patients, caregivers, and providers in identifying resources that may ease that burden by providing easy access to payment assistance and reimbursement programs, respectively.”
Available for both Apple and Android mobile devices, the NCCN Reimbursement Resource App includes interfaces tailored for each of three audiences—patient or caregiver, payer or case manager, and physician or provider—through which users can search for payment programs by three categories: cancer type or supportive care indication, drug name, or reimbursement or assistance program.
Content contained within the NCCN Reimbursement Resource App is updated simultaneously with the NCCN Virtual Reimbursement Resource Room on NCCN.org. The NCCN Virtual Reimbursement Resource Room was launched in 2009 in an effort to provide a payment assistance information resource that covered a variety of cancer types and supportive care indications.
Technical development of this mobile app is supported by ARIAD Pharmaceuticals, Inc.; Genentech, a Member of the Roche Group; and Teva Oncology.
For more information about the NCCN Reimbursement Resource App, visit NCCN.org.
Apple is a trademark of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc.
Google Play is a trademark of Google Inc. Android is a registered trademark of Google.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer Center at The Nebraska Medical Center, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.